Journal article · 2026 · Open access

Democratising real-world drug discovery through agentic AI

Jiazhen He, Helen Lai, Lakshidaa Saigiridharan, Gian Marco Ghiandoni, K. Jenei, Umur Gokalp, Ajsa Nukovic, Ola Engkvist, Jon Paul Janet, Samuel Genheden

Drug Discovery Today, 31(2), 104605 · Published 16 January 2026 · DOI 10.1016/j.drudis.2026.104605

Open full textCite this paper

In brief

“Democratising real-world drug discovery through agentic AI” is a 2026 journal article by Jiazhen He and 9 co-authors, published in Drug Discovery Today. OpenAlex counts 30 citations as of 17 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Drug Discovery Today.

Citations
30
Most cited in
2026 (30)
Field-weighted impact
37.96
References
22
Authors
10

Abstract

• Agentic systems are an emerging technology for automation, but evidence of their real-world use in drug discovery is limited. • We present AstraZeneca’s agentic systems LangDMTA and ChatInvent, outlining implementation challenges and lessons learned. ChatInvent, a conversational interface for agentic drug discovery, is illustrated with a typical use case. • Key technical considerations are discussed, including architecture choice, automated testing for continuous integration, and benchmarking. • Practical recommendations are provided for building agentic systems in drug discovery. • We speculate on the potential of agentic systems for improving efficiency in pharmaceutical R&D. Agentic systems that are based on large language models (LLMs) have emerged as promising tools in the chemistry domain over the past few years. Early examples included work on CoScientist, Chemcrow, and LLM-RDF, which showcased the potential of agentic systems to assist in chemical research, in the orchestration of cheminformatics tools, and in synthetic reaction development. Despite this, the current literature lacks examples of the real-world adoption of such systems in drug discovery. We present such an example by describing our work on an agentic system called ChatInvent, which has been integrated into the discovery pipeline at AstraZeneca to aid in molecular design and synthesis planning. We discuss how the system evolved from a proof-of-concept single agent into an extensible, robust, and scalable multi-agent architecture with a graphical user interface. We emphasize the lessons learnt and the challenges that persist as we continue to work on this project, and share our perspectives on the future of agentic systems in our domain.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

He, J., Lai, H., Saigiridharan, L., Ghiandoni, G. M., Jenei, K., Gokalp, U., Nukovic, A., Engkvist, O., Janet, J. P., & Genheden, S. (2026). Democratising real-world drug discovery through agentic AI. Drug Discovery Today, 31(2), 104605. https://doi.org/10.1016/j.drudis.2026.104605

MLA 9

He, Jiazhen, et al. “Democratising real-world drug discovery through agentic AI.” Drug Discovery Today, vol. 31, no. 2, 2026, p. 104605. https://doi.org/10.1016/j.drudis.2026.104605.

Chicago

He, Jiazhen, Helen Lai, Lakshidaa Saigiridharan, Gian Marco Ghiandoni, K. Jenei, Umur Gokalp, Ajsa Nukovic, Ola Engkvist, Jon Paul Janet, and Samuel Genheden. 2026. “Democratising real-world drug discovery through agentic AI.” Drug Discovery Today 31 (2): 104605. https://doi.org/10.1016/j.drudis.2026.104605.

Harvard

He, J. et al. (2026) ‘Democratising real-world drug discovery through agentic AI’, Drug Discovery Today, 31(2), p. 104605. doi:10.1016/j.drudis.2026.104605.

IEEE

J. He et al., “Democratising real-world drug discovery through agentic AI,” Drug Discovery Today, vol. 31, no. 2, p. 104605, 2026, doi: 10.1016/j.drudis.2026.104605.

BibTeX

@article{he2026democratising,
  title     = {{Democratising real-world drug discovery through agentic AI}},
  author    = {He, Jiazhen and Lai, Helen and Saigiridharan, Lakshidaa and Ghiandoni, Gian Marco and Jenei, K. and Gokalp, Umur and Nukovic, Ajsa and Engkvist, Ola and Janet, Jon Paul and Genheden, Samuel},
  journal   = {Drug Discovery Today},
  year      = {2026},
  volume    = {31},
  number    = {2},
  pages     = {104605},
  doi       = {10.1016/j.drudis.2026.104605},
  url       = {https://doi.org/10.1016/j.drudis.2026.104605}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • agentic AI
  • large language models
  • drug discovery
  • multi-agent architecture
  • molecular design
  • synthesis planning
  • conversational interfaces
  • continuous integration testing

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

He, J., Lai, H., Saigiridharan, L., Ghiandoni, G. M., Jenei, K., Gokalp, U., Nukovic, A., Engkvist, O., Janet, J. P., & Genheden, S. (2026). Democratising real-world drug discovery through agentic AI. Drug Discovery Today, 31(2), 104605. https://doi.org/10.1016/j.drudis.2026.104605

How many times has this paper been cited?

30 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Drug Discovery Today: sign in and open the full text from this page.

Who wrote this paper?

Jiazhen He, Helen Lai, Lakshidaa Saigiridharan, Gian Marco Ghiandoni, K. Jenei, Umur Gokalp, Ajsa Nukovic, Ola Engkvist, Jon Paul Janet, Samuel Genheden.

What is the DOI of this paper?

10.1016/j.drudis.2026.104605, permanently at https://doi.org/10.1016/j.drudis.2026.104605. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.